Why Did CERo Therapeutics Plunge 20.52% Amid Volatility?

On June 18, 2025, CERo Therapeutics experienced a significant drop of 20.52% in pre-market trading, reflecting heightened market volatility and investor caution.

CERo Therapeutics Holdings Inc. recently faced a trading halt due to market volatility, which contributed to the stock's decline. This halt was implemented as a precautionary measure to stabilize trading and prevent further volatility.

The company's short interest, which represents the number of shares sold short as a percentage of the float, stands at 11.78%. This high short interest indicates that a significant portion of the stock is being bet against, which can exacerbate price volatility.

Additionally, CERo Therapeutics recently announced that it has received FDA Orphan Drug Designation for CER-1236, a drug aimed at treating a specific type of blood cancer. This designation is a significant milestone for the company, as it provides incentives for developing treatments for rare diseases and can enhance the stock's appeal to investors.

However, the company also performed a 1 for 20 reverse stock split, which means shareholders now hold 1 share for every 20 shares they previously owned. This move is often used to increase the stock price and attract more investors, but it can also signal underlying financial concerns.